Articles related to Pediatrics

In this article/podcast from KevinMD.com, the author encourages readers to make some adjustments in their life to reduce the professional and personal risks associated with the stakeholders who target physicians, including corporate America, the government, patients, and the financial industry. The commentary is a response to President Biden’s multi-trillion spending plan, which targets rich corporations and wealthy individual Americans making more than $400,000.

The recommendations from the American Academy of Pediatrics (AAP) are an update to the group’s 2012 policy statement in an effort to better equip physicians with the necessary knowledge to accurately screen, evaluate, and manage the risk of both sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in youth. Screening for all children, regardless of athletic status, should be completed at least every three years.

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy seen in children and adolescents and young adults (AYAs). This article highlights two recent studies that provide novel evidence of the association between obesity and increased risk of high-risk B-ALL and the effectiveness of a non-pharmacologic intervention for reducing minimal residual disease (MRD) risk.

Although most skin problems are harmless, a minor one can become serious in people who have diabetes. Whether it’s the common skin tag or more tongue-twisting things like necrobiosis lipoidica, you should be aware of the dermatologic conditions that could be precursors or signs of diabetes in your patients. With images and descriptions, this resource will provide a great review of the conditions.

The data was presented to the FDA, which reported 789 cases of myocarditis/pericarditis – predominantly in males – after receiving the Pfizer/BioNTech and Moderna vaccines, most commonly after the second dose. Symptoms included chest pain, elevated cardiac enzymes, ST or T wave changes, dyspnea, and abnormal echocardiography/imaging for those ages 30 years and younger.

It’s a battle of two heavyweights in this trial report from the Journal of Clinical Oncology, sharing the results of acalabrutinib (Calquence) compared to ibrutinib (Imbruvica) in treating chronic lymphocytic leukemia (CLL). Selected events of clinical interest included cardiac events, atrial fibrillation, ventricular tachyarrhythmias, hypertension, bleeding and major bleeding events, infections, and second primary malignancies excluding non-melanoma skin cancers.